Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 439

1.

Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study.

Siwek M, Dudek D, Paul IA, Sowa-Kućma M, Zieba A, Popik P, Pilc A, Nowak G.

J Affect Disord. 2009 Nov;118(1-3):187-95. doi: 10.1016/j.jad.2009.02.014. Epub 2009 Mar 10.

PMID:
19278731
2.

Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study.

Nowak G, Siwek M, Dudek D, Zieba A, Pilc A.

Pol J Pharmacol. 2003 Nov-Dec;55(6):1143-7.

4.
5.

Effect of metyrapone supplementation on imipramine therapy in patients with treatment-resistant unipolar depression.

Rogóz Z, Skuza G, Wójcikowski J, Daniel WA, Wróbel A, Dudek D, Zieba A.

Pol J Pharmacol. 2004 Nov-Dec;56(6):849-55.

6.
7.

Treatment of mood-congruent psychotic depression with imipramine.

Bruijn JA, Moleman P, Mulder PG, van den Broek WW.

J Affect Disord. 2001 Oct;66(2-3):165-74.

PMID:
11578669
8.

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW.

J Clin Psychopharmacol. 2008 Dec;28(6):631-7. doi: 10.1097/JCP.0b013e31818a6cea.

PMID:
19011431
9.

Serum zinc level in depressed patients during zinc supplementation of imipramine treatment.

Siwek M, Dudek D, Schlegel-Zawadzka M, Morawska A, Piekoszewski W, Opoka W, Zieba A, Pilc A, Popik P, Nowak G.

J Affect Disord. 2010 Nov;126(3):447-52. doi: 10.1016/j.jad.2010.04.024. Epub 2010 May 20.

PMID:
20493532
10.

A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine.

Carpenter LL, Yasmin S, Price LH.

Biol Psychiatry. 2002 Jan 15;51(2):183-8.

PMID:
11822997
11.

Effects of joint administration of imipramine and amantadine in patients with drug-resistant unipolar depression.

Rogóz Z, Dziedzicka-Wasylewska M, Daniel WA, Wójcikowski J, Dudek D, Wróbel A, Zieba A.

Pol J Pharmacol. 2004 Nov-Dec;56(6):735-42.

12.
13.

Influence of zinc supplementation on imipramine effect in a chronic unpredictable stress (CUS) model in rats.

Cieślik K, Klenk-Majewska B, Danilczuk Z, Wróbel A, Łupina T, Ossowska G.

Pharmacol Rep. 2007 Jan-Feb;59(1):46-52.

14.

Antidepressant efficacy of sertraline and imipramine for the treatment of major depression in elderly outpatients.

Forlenza OV, Stoppe Júnior A, Hirata ES, Ferreira RC.

Sao Paulo Med J. 2000 Jul 6;118(4):99-104.

15.

Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression.

Rogóz Z, Skuza G, Daniel WA, Wójcikowski J, Dudek D, Wróbel A.

Pharmacol Rep. 2007 Nov-Dec;59(6):778-84.

16.

Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation.

da Silva TM, Munhoz RP, Alvarez C, Naliwaiko K, Kiss A, Andreatini R, Ferraz AC.

J Affect Disord. 2008 Dec;111(2-3):351-9. doi: 10.1016/j.jad.2008.03.008. Epub 2008 May 15.

PMID:
18485485
18.
19.

Lithium but not carbamazepine augments antidepressant efficacy of mirtazapine in unipolar depression: an open-label study.

Schüle C, Baghai TC, Eser D, Nothdurfter C, Rupprecht R.

World J Biol Psychiatry. 2009;10(4 Pt 2):390-9. doi: 10.1080/15622970701849978.

PMID:
18609420
20.

Relapse prevention by means of paroxetine in ECT-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy.

Lauritzen L, Odgaard K, Clemmesen L, Lunde M, Ohrström J, Black C, Bech P.

Acta Psychiatr Scand. 1996 Oct;94(4):241-51.

PMID:
8911559

Supplemental Content

Support Center